Biopharmaceutical R&D Productivity 2016

Biopharmaceutical R&D Productivity 2016


324 exhibits

269 pages


SKU: 160707RD. Categories: , .


This 269-page, 324 exhibit report published August 2016 objectively characterizes past, current and projected future levels of R&D productivity for the 22 largest US-listed R&D firms. For the entire group of companies and for each individual company, we track a comprehensive set of performance metrics, including:

Economic returns to R&D spending

Innovation yield on R&D spending

Average quality of innovation

Pipeline adequacy and composition (by mechanism of action and targeted therapeutic area)

Discovery/early development effort and focus

Internal development bias

And rank companies v. the peer group in aggregate, and across individual components of R&D performance.

There are no reviews yet.

Be the first to review “Biopharmaceutical R&D Productivity 2016”